These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 16467077

  • 1. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
    Granville CA, Memmott RM, Gills JJ, Dennis PA.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):679-89. PubMed ID: 16467077
    [Abstract] [Full Text] [Related]

  • 2. Targeting Akt in cancer therapy.
    LoPiccolo J, Granville CA, Gills JJ, Dennis PA.
    Anticancer Drugs; 2007 Sep 01; 18(8):861-74. PubMed ID: 17667591
    [Abstract] [Full Text] [Related]

  • 3. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA.
    Expert Opin Investig Drugs; 2009 Sep 01; 18(9):1333-49. PubMed ID: 19678801
    [Abstract] [Full Text] [Related]

  • 4. Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway.
    Chenal J, Pellerin L.
    J Neurochem; 2007 Jul 01; 102(2):389-97. PubMed ID: 17394554
    [Abstract] [Full Text] [Related]

  • 5. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
    Xu Y, Chen SY, Ross KN, Balk SP.
    Cancer Res; 2006 Aug 01; 66(15):7783-92. PubMed ID: 16885382
    [Abstract] [Full Text] [Related]

  • 6. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C, Figlin RA.
    J Urol; 2009 Dec 01; 182(6):2569-77. PubMed ID: 19836781
    [Abstract] [Full Text] [Related]

  • 7. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P.
    Curr Opin Pharmacol; 2008 Aug 01; 8(4):393-412. PubMed ID: 18721898
    [Abstract] [Full Text] [Related]

  • 8. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
    Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A.
    Cancer Res; 2009 Feb 01; 69(3):1027-36. PubMed ID: 19176369
    [Abstract] [Full Text] [Related]

  • 10. Targeting mTOR signaling in lung cancer.
    Marinov M, Fischer B, Arcaro A.
    Crit Rev Oncol Hematol; 2007 Aug 01; 63(2):172-82. PubMed ID: 17540577
    [Abstract] [Full Text] [Related]

  • 11. A role for Akt in epidermal growth factor-stimulated cell cycle progression in cultured hepatocytes: generation of a hyperproliferative window after adenoviral expression of constitutively active Akt.
    Luo Y, Dixon CJ, Hall JF, White PJ, Boarder MR.
    J Pharmacol Exp Ther; 2007 Jun 01; 321(3):884-91. PubMed ID: 17371807
    [Abstract] [Full Text] [Related]

  • 12. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
    Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A.
    Clin Cancer Res; 2008 May 01; 14(9):2673-80. PubMed ID: 18451231
    [Abstract] [Full Text] [Related]

  • 13. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
    Georgakis GV, Younes A.
    Expert Rev Anticancer Ther; 2006 Jan 01; 6(1):131-40. PubMed ID: 16375650
    [Abstract] [Full Text] [Related]

  • 14. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway.
    Lohar MV, Mundada R, Bhonde M, Padgaonkar A, Deore V, Yewalkar N, Bhatia D, Rathos M, Joshi K, Vishwakarma RA, Kumar S.
    Bioorg Med Chem Lett; 2008 Jun 15; 18(12):3603-6. PubMed ID: 18501601
    [Abstract] [Full Text] [Related]

  • 15. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O, Almazan G.
    J Neurochem; 2009 Jun 15; 109(5):1440-51. PubMed ID: 19453943
    [Abstract] [Full Text] [Related]

  • 16. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.
    Olsen BB, Bjørling-Poulsen M, Guerra B.
    Int J Biochem Cell Biol; 2007 Jun 15; 39(1):227-37. PubMed ID: 17018259
    [Abstract] [Full Text] [Related]

  • 17. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions.
    Kaper F, Dornhoefer N, Giaccia AJ.
    Cancer Res; 2006 Feb 01; 66(3):1561-9. PubMed ID: 16452213
    [Abstract] [Full Text] [Related]

  • 18. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
    Woodard J, Sassano A, Hay N, Platanias LC.
    Clin Cancer Res; 2008 Jul 15; 14(14):4640-9. PubMed ID: 18628479
    [Abstract] [Full Text] [Related]

  • 19. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
    Garcia-Echeverria C, Sellers WR.
    Oncogene; 2008 Sep 18; 27(41):5511-26. PubMed ID: 18794885
    [Abstract] [Full Text] [Related]

  • 20. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.
    Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ.
    Curr Opin Investig Drugs; 2005 Dec 18; 6(12):1250-8. PubMed ID: 16370391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.